Nirmatrelvir-ritonavir efficacy in special populations – Insights from comparative studies
16 Sep 2024
Nirmatrelvir-ritonavir has emerged as a key antiviral therapy in the fight against COVID-19, particularly for high-risk populations. Two recently published studies demonstrated the efficacy of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and in those with advanced kidney disease.
Resources
Nirmatrelvir-ritonavir efficacy in special populations – Insights from comparative studies
Nirmatrelvir-ritonavir efficacy in special populations – Insights from comparative studies